Turn Therapeutics Inc. reported a net loss of $1.9 million for the three months ended September 30, 2025, compared to a net loss of $0.7 million for the same period in 2024. General and administrative expenses rose to $1.8 million from $0.5 million, mainly due to increased legal and advisory fees associated with the company's direct listing on Nasdaq. As of September 30, 2025, the company had $3.1 million in cash and cash equivalents, up from $0.9 million at the end of 2024. Turn Therapeutics began trading on Nasdaq on October 8, 2025, and expanded its board and executive team during the period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574408-en) on November 13, 2025, and is solely responsible for the information contained therein.